ProCE Banner Activity

How I Manage Adverse Events Associated With BTK Inhibitors

Clinical Thought
With the approval and clinical availability of BTK inhibitors, are you effectively managing the associated toxicities in your patients with lymphomas to get the most out of these agents?

Released: March 08, 2019

Expiration: March 06, 2020

Share

Faculty

Jeremy S Abramson

Jeremy S Abramson, MD, MMSc

Director, Center for Lymphoma
Mass General Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Janssen administered by Scientific Affairs

Pharmacyclics an AbbVie Company

Faculty Disclosure

Primary Author

Jeremy S Abramson, MD, MMSc

Director, Center for Lymphoma
Mass General Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Jeremy S. Abramson, MD, MMSc, has disclosed that he has received consulting fees from Abbvie, Amgen, Celgene, Gilead, Humanigen, Juno, Karyopharm, Merck, Novartis, Seattle Genetics, and Verastem.